|
|
|
Stem Cell Related Patent Number US6255112
| Title: | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells | | Inventors: | Thiede, Mark A.; Forest Hill, MD, USA | | Summary: | This invention relates to a process of producing osteoclasts in vitro. Described herein are methods of inducing hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, preferably without exogenous cytokines, such that the differentiation of the mesenchymal stem cells into osteoblasts was found to inhibit the differentiation of hematopoietic stem cells into osteoclasts. Further disclosed are methods by which the hematopoietic stem cells can be genetically engineered to carry genes of interest, particularly for the expression of physiologically active proteins, such that, in the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products which can be used to modulate bone resorption. | | Abstract: | The invention relates to the induction of hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, and, in a preferred embodiment, using no exogenous cytokines. Differentiation of the mesenchymal stem cells into osteoblasts inhibited the differentiation of hematopoietic stem cells into osteoclasts. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate bone resorption. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US6255112 | | Application Number: | US1999000327796 | | Date Filed: | 08/06/1999 | | Date Published: | 03/07/2001 | | Assignee: | Osiris Therapeutics, Inc., Baltimore, MD, USA |
|
|
